Athira Pharma
Founded Year
2011Stage
IPO | IPOTotal Raised
$116.02MDate of IPO
9/18/2020Market Cap
0.11BStock Price
3.06About Athira Pharma
Athira Pharma (NASDAQ: ATHA) is a drug development company that strives to improve human health by advancing new therapies for neurodegenerative diseases, like Alzheimer's and Parkinson's. The company's approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.
Athira Pharma Headquarter Location
4000 Mason Road Suite 300
Seattle, Washington, 98195,
United States
206-221-8112
Expert Collections containing Athira Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Athira Pharma is included in 2 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Athira Pharma Patents
Athira Pharma has filed 2 patents.
The 3 most popular patent topics include:
- Neurological disorders
- Neurotrauma
- Rare diseases
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/1/2017 | 6/1/2021 | Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders | Grant |
Application Date | 6/1/2017 |
|---|---|
Grant Date | 6/1/2021 |
Title | |
Related Topics | Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders |
Status | Grant |
Latest Athira Pharma News
Jun 24, 2022
Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter: Latest Ratings for ATHA DateFirmActionFromTo Dec 2021Goldman SachsInitiates Coverage OnNeutral Oct 2020JefferiesInitiates Coverage OnBuy Oct 2020JMP SecuritiesInitiates Coverage OnMarket Outperform View More Analyst Ratings for ATHA View the Latest Analyst Ratings read more
Athira Pharma Web Traffic
Athira Pharma Rank
When was Athira Pharma founded?
Athira Pharma was founded in 2011.
Where is Athira Pharma's headquarters?
Athira Pharma's headquarters is located at 4000 Mason Road, Seattle.
What is Athira Pharma's latest funding round?
Athira Pharma's latest funding round is IPO.
How much did Athira Pharma raise?
Athira Pharma raised a total of $116.02M.
Who are the investors of Athira Pharma?
Investors of Athira Pharma include Surveyor Capital, Logos Capital, RTW Investments, Venrock, Highside Capital Management and 23 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.